Latest "Galectin Therapeutics" News Stories

21:52 EST 3rd March 2015 | BioPortfolio

Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Galectin Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.

Showing "Galectin Therapeutics" News Articles 1–25 of 58

Relevant

Galectin-3 and Plasma Cytokines in Patients With Acute MI

Could the protein galectin-3 be useful as a circulating biomarker of inflammation associated with acute myocardial infarction? Laboratory Medicine

Bristol-Myers signs exclusive option deal to buy Galecto and new Galectin-3 inhibitor

Bristol-Myers Squibb (BMS) has signed an exclusive option agreement to acquire Denmark-based Galecto Biotech and secure worldwide rights to a new inhaled inhibitor of galectin-3, TD139.

Bristol-Myers Squibb to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor

Bristol-Myers Squibb Company and Galecto Biotech AB have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of g...

Patent Awarded for Innovative Galectin-3 Plasmapheresis Therapy

SANTA ROSA, Calif., Sept. 4, 2014 /PRNewswire/ -- Isaac Eliaz, MD, MS, LAc has been awarded a USA patent as well as additional international patents for a therapeutic process that allows for the removal of excess galectin-3 from the circulatory system using plasmapheresis. The Galectin-3 Plasmapheresis Therapy patent is the first-ever granted for this type of therapy. Dr. Eliaz is a pioneer...

Bristol-Myers Squibb to acquire Galecto Biotech AB and its novel Galectin-3 Inhibitor in development for Idiopathic Pulmonary Fibrosis

Bristol-Myers Squibb Company and Galecto Biotech AB have announced that the companies, together with the Galecto shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and ga...

GALECTIN 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against Galectin Therapeutics Inc. - GALT

NEW ORLEANS, LA -- (Marketwired) -- 09/26/14 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financia...

Galectin Therapeutics Announces Issuance of U.S. Patent for GR-MD-02 in Diabetic Nephropathy

NORCROSS, Ga., Sept. 15, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the U.S. Patent and Trademark Office has issued a patent for the Company's application titled "Galactose-Pronged Carbohydrate Compounds for the Treatment of Diabetic Nephropathy and Associ...

Galectin Therapeutics Announces Details of the Design of Its Phase 2 Program With GR-MD-02

Program to include one trial to confirm the safety and therapeutic effect on fibrosis in NASH patients with cirrhosis, and a smaller trial to confirm the safety and therapeutic effect on NASH patients with advanced fibrosis Both studies to begin in the second quarter of 2015 Company to submit a Special Protocol Assessment to the FDA by the end of the month NORCROSS, Ga., Feb. 24...

Galectin Therapeutics to Present at the 27th Annual ROTH Conference

NORCROSS, Ga., March 2, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that Harold, Shlevin, Ph.D, chief operating officer, will present a corporate overview and update at the 27th Annual ROTH Conference on March 9, 2015 at 11:00 a.m. Pacific time. The conference is bei...

Galectin Therapeutics, Inc. - Product Pipeline Review - 2014

Recently added to the BioPortfolio report store, Galectin Therapeutics, Inc. - Product Pipeline Review - 2014 is a new report from Global Markets Direct published on 2014-12-14. This 40-page report is available in PDF from $1500. Galectin Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct’s, ‘Galectin Therapeutics, Inc. - Product Pipeline Review - 2014’, prov...

Galectin Therapeutics to Present at Aegis Capital Corporation 2014 Healthcare and Technology Conference

NORCROSS, Ga., Sept. 10, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the Company will present at the Aegis Capital Corporation 2014 Healthcare and Technology Conference in Las Vegas, Nev., on Friday, September 12, 2014 at 1 p.m. Pacific Daylight Time. Peter G. T...

Galectin Therapeutics to Present at 7th Annual LD Micro Main Event Conference

NORCROSS, Ga., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that James C. Czirr, executive chairman of the Company's board of directors, will present at the LD Micro "Main Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014 at 11:30 a.m. PST...

The 2015 Calendar Of NASH Trial Catalysts II: Galectin Therapeutics And La Jolla Pharmaceutical Co.

Galectin Therapeutics Elects Gilbert S. Omenn, M.D., Ph.D., a Leading Cancer Researcher, to Its Board of Directors

NORCROSS, Ga., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the election of Gilbert S. Omenn, M.D., Ph.D., to its Board of Directors, effective immediately. Dr. Omenn, a leading cancer researcher, is a professor of internal medicine, human genetics and ...

Regulation of osteoclastogenesis through Tim-3: possible involvement of the Tim-3/galectin-9 system in the modulation of inflammatory bone destruction

Galectin Therapeutics Reports Third Quarter 2014 Financial Results and Provides Update on Company's Development Program

NORCROSS, Ga., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the third quarter and nine months ended September 30, 2014. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the Secu...

Galmed surges on NASH news

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) jumped $2.45 (38%) to $8.93 on Tuesday after FDA granted Fast Track designation to Aramchol arachidyl amino cholanoic acid to treat non-alcoholic steatohepatitis (NASH).Galmed plans to begin a Phase IIb trial...

The Galectin-9/Tim-3 pathway is involved in the regulation of NK cell function at the maternal–fetal interface in early pregnancy

Hagens Berman Reminds Investors in Galectin Therapeutics, Inc. of the Sept. 29, 2014 Lead Plaintiff Class-Action Deadline

SAN FRANCISCO, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP, a top-tier investor-rights law firm, advises investors of the Sept. 29, 2014, lead plaintiff deadline in the securities fraud class action against Galectin Therapeutics Inc. (Nasdaq:GALT) ("Galectin" or "the Company"). Investors who purchased Galectin shares between January 6, 2014 and July 28, 2014 (the "Class Peri...

BG Medicine, Inc. Welcomes Presentation of Clinical Data on Galectin-3 Testing at the American Heart Association 2014 Scientific Sessions Conference

WALTHAM, Mass., Nov. 20, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, announced today that 17 abstracts reporting independent research that investigates galectin-3 testing in various cardiovascular diseases have been presented at the American Heart Association's 2014 Scientific Sessions and Resuscitation Science Symposium, which was held in...

EQUITY ALERT: Rosen Law Firm Reminds Galectin Therapeutics, Inc. Investors of Important September 29, 2014 Class Action Deadline -- GALT

NEW YORK, Sept. 26, 2014 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. reminds purchasers of Galectin Therapeutics, Inc. (Nasdaq:GALT) securities between January 6, 2014 and July 28, 2014, of the important September 29, 2014 lead plaintiff deadline in the class action. To join the Galectin class action, visit the firm's website at http://www.rosenlegal.com/cases-322.html, or call Phillip Kim or ...

Bristol-Myers secures option to buy Danish firm behind inhaled IPF drug

Bristol-Myers Squibb has secured an exclusive option to acquire Galecto Biotech and gain worldwide rights to its lead asset TD139, a pipeline drug for idiopathic pulmonary fibrosis and other pulmonary fibrotic conditions.Idiopathic pulmonary fibrosis...

Galectin Therapeutics' Phase 1 Data Presented at AASLD Annual Meeting Advances GR-MD-02 Into Phase 2 Clinical Development

NORCROSS, Ga., Nov. 9, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, presented data today from the Company's Phase 1 clinical trial of GR-MD-02 in NASH (fatty liver disease) patients with advanced fibrosis at The Liver Meeting in Boston, Massachusetts. Stephen A. Harrison, MD, Ch...

Dual attack in IPF

Galecto thinks the dual mechanism and local delivery of its TD139 galectin-3 inhibitor can provide better efficacy and safety in IPF.

Final Phase 1 Trial Results Demonstrate Galectin Therapeutics' GR-MD-02 is Safe With Potential for Therapeutic Effect on Fibrosis in NASH Patients With Advanced Fibrosis

NORCROSS, Ga., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that final results from its Phase 1 trial show that GR-MD-02 had an effect on a serum biomarker (as assessed by FibroTest®) and liver stiffness (as assessed by FibroScan®) that suggest a potential for the...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks